Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Q24235596)

1 July 2019

meta-analysis

0 references

review article

1 reference

title

Insulin detemir versus insulin glargine for type 2 diabetes mellitus (English)

1 reference

1 July 2019

0 references

1 reference

1 reference

1 reference

5

J Hans Devries

J Hans

Devries

1 reference

1 July 2019

Sanne G Swinnen

1

Sanne G

Swinnen

1 reference

1 July 2019

Joost B Hoekstra

series ordinal

4

author given names

Joost B

author last names

Hoekstra

1 reference

1 July 2019

Airin Cr Simon

series ordinal

2

author given names

Airin Cr

author last names

Simon

1 reference

1 July 2019

Frits Holleman

author given names

Frits

author last names

Holleman

series ordinal

3

1 reference

19 October 2023

6 July 2011

1 reference

1 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

1 July 2019

issue

7

1 reference

1 July 2019

page(s)

CD006383

1 reference

1 July 2019

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Insulin analogues and their potential in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006383.PUB2

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21735405

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21735405

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/14651858.CD006383.PUB2

1 reference

1 July 2019

release_h2i5msfvxvbj5m7kbscwdhv4we

Fatcat ID

0 references

OpenCitations bibliographic resource ID

4847686

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

1 July 2019

PubMed ID

21735405

1 reference

1 July 2019